1,4-Bis(3-carboxy-4-hydroxyphenylethenyl)-benzene | 215294-98-7

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 二苯乙烯类
• 英文名称: 1,4-Bis(3-carboxy-4-hydroxyphenylethenyl)-benzene
• 英文别名: 5-[2-[4-[2-(3-carboxy-4-hydroxyphenyl)ethenyl]phenyl]ethenyl]-2-hydroxybenzoic acid
• CAS: 215294-98-7
• 化学式: C₂₄H₁₈O₆
• 分子量: 402.403
• InChiKey: MCBNOAYTZBUCSX-UHFFFAOYSA-N

物化性质

• 沸点：
  669.9±55.0 °C(Predicted)
• 密度：
  1.448±0.06 g/cm3(Predicted)
• 溶解度：
  DMSO: 2.0mg/mL, clear

计算性质

• 辛醇/水分配系数(LogP)：
  5.9
• 重原子数：
  30
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  115
• 氢给体数：
  4
• 氢受体数：
  6

制备方法与用途

X-34 是一种亲脂性的、明亮的黄绿色荧光衍生物，具体为刚果红（Congo Red, HY-D0236）。它可用于对大脑中的神经炎性和弥漫性斑块、神经原纤维缠结（NFT）、神经纤维网线和脑血管淀粉样蛋白进行染色，并广泛应用于阿尔茨海默病的研究。

文献信息

• REDUCING Abeta42 LEVELS AND Abeta AGGREGATION
  申请人：Golde Todd E.

  公开号：US20110021471A1

  公开（公告）日：2011-01-27

  This document relates to methods and materials for reducing Aβ42 levels, reducing Aβ aggregation, or reducing both Aβ42 levels and Aβ aggregation. For example, this document provides methods and materials related to the use of agents (e.g., 5β-cholanic acid) to reduce Aβ42 levels and to reduce Aβ aggregation in mammals.

  这份文件涉及减少Aβ42水平、减少Aβ聚集或同时减少Aβ42水平和Aβ聚集的方法和材料。例如，这份文件提供了使用药剂（例如5β-胆酸）在哺乳动物中减少Aβ42水平和减少Aβ聚集的方法和材料。
• IMAGE DIAGNOSIS PROBE BASED ON SUBSTITUTED AZOBENZENE OR ANALOGUE THEREOF FOR DISEASE ATTRIBUTABLE TO AMYLOID ACCUMULATION AND COMPOSITION FOR IMAGE DIAGNOSIS CONTAINING THE SAME
  申请人：BF Research Institute, Inc.

  公开号：EP1266884A1

  公开（公告）日：2002-12-18

  A compound represented by the formula (I):         (R1)m―A―X-----Y―B―(R2)n     (I) or a salt or a solvate thereof; and a composition and a kit both containing any of these. In said formula I, X represents CH, Sulfur, or nitrogen; Y represents CH, sulfur or nitrogen, or absent; ----- means a single bond or a double bond; A and B each independently represents a benzene ring or six-membered heterocyclic containing one or two atoms of nitrogen, oxygen, or sulfur; and R1 and R2 represent one to seven substituents of ring A and ring B, respectively.

  式 (I) 所代表的化合物： (R1)m-A-X-----Y-B-(R2)n (I) 或其盐或溶解物；以及含有其中任何一种的组合物和试剂盒。在所述式 I 中，X 代表 CH、硫或氮；Y 代表 CH、硫或氮，或不存在；----- 指单键或双键；A 和 B 各自独立地代表苯环或含有一个或两个氮、氧或硫原子的六元杂环；R1 和 R2 分别代表环 A 和环 B 的一至七个取代基。
• Methods and kits for detecting misfolded proteins
  申请人：Yale University

  公开号：US11125758B2

  公开（公告）日：2021-09-21

  Methods, kits and compounds are provided that relate to the diagnosis, treatment, and/or prevention of preeclampsia.

  提供了与诊断、治疗和/或预防子痫前期有关的方法、试剂盒和化合物。
• Image diagnosis probe based on substituted azobenzene or analogue thereof for disease attributable to amyloid accumulation and composition for image diagnosis containing the same
  申请人：——

  公开号：US20030138374A1

  公开（公告）日：2003-07-24

  A compound represented by the formula (I): (R 1 ) m -A—X Y-B—(R 2 ) n (I) or a salt or a solvate thereof; and a composition and a kit both containing any of these. In said formula I, X represents CH, Sulfur, or nitrogen; Y represents CH, sulfur or nitrogen, or absent; means a single bond or a double bond; A and B each independently represents a benzene ring or six-membered heterocyclic containing one or two atoms of nitrogen, oxygen, or sulfur; and R 1 and R 2 represent one to seven substituents of ring A and ring B, respectively.

  由式(I)代表的化合物： (R 1 ) m -A-X Y-B-(R 2 ) n (I) 或其盐或溶解物；以及含有上述任一成分的组合物和试剂盒。在所述式 I 中，X 代表 CH、硫或氮；Y 代表 CH、硫或氮，或不存在； 指单键或双键；A 和 B 各自独立地代表苯环或含有一个或两个氮、氧或硫原子的六元杂环；以及 R 1 和 R 2 分别代表环 A 和环 B 的一至七个取代基。
• Sequestration of ass in the periphery in the absence of immunomodulating agent as a therapeutic approach for the treatment or prevention of beta-amyloid related diseases
  申请人：Duff Karen

  公开号：US20050227941A1

  公开（公告）日：2005-10-13

  The present invention describes a method of administering an Aβ-binding agent or drug which has affinity for amyloid beta (Aβ) in the periphery (blood) and reducing Aβ levels in the brain without the need for the agent or drug to enter the brain itself. The Aβ-binding agents utilized in the methods of the invention are preferably non-immunomodulating agents (e.g., antigenic peptides or antibodies) and bind to Aβ in the periphery, or blood. Such compounds do not significantly cross the blood/brain barrier, and yet they lower amyloid (Aβ) levels in the brain, thereby serving as safer, therapeutic and prophylactic treatments against diseases associated with Aβ in the brain, e.g., Alzheimer's Disease and amyloid angiopathy, as well as against other AD-related amyloidoses.

  本发明描述了一种施用Aβ结合剂或药物的方法，这种结合剂或药物与外周（血液）中的淀粉样β（Aβ）具有亲和力，并能降低大脑中的Aβ水平，而不需要制剂或药物进入大脑本身。本发明方法中使用的 Aβ 结合剂最好是非免疫调节剂（如抗原肽或抗体），并与外周或血液中的 Aβ 结合。这类化合物不会明显穿过血/脑屏障，但却能降低大脑中的淀粉样蛋白（Aβ）水平，因此可作为更安全的治疗和预防性疗法，用于治疗与大脑中的 Aβ 有关的疾病，如阿尔茨海默病和淀粉样血管病，以及其他与 AD 有关的淀粉样变性疾病。